Familial defective apolipoprotein B-100 (FDB): Effect of simvastatin therapy on LDL-receptor binding

Atherosclerosis

Volumn 125, Issue 1, 1996, Pages 103-110

  Mamotte, Cyril D S ^a   Sturm, Marian ^a   Foo, Jock I ^a   Van Bockxmeer, Frank M ^a   Taylor, Roger R ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Familial defective apolipoprotein B 100; HMGCoA reductase inhibitors; LDL receptor; Simvastatin

Indexed keywords

APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODINE 125; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; LIPOGENESIS; MALE; PRIORITY JOURNAL; RADIOIODINATION; RECEPTOR BINDING;

EID: 0030598950     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05867-4     Document Type: Article

References (25)

1. [1] Innerarity TL, Mahley RW, Weisgraber KH et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolaemia. J Lip Res 1990;31:1337.
2. [2] Pullinger CR, Hennessy LK, Chatterton JE et al. Familial ligand defective apolipoprotein B - Identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest 1995;95:1225.
3. [3] Illingworth DR, Vakar F, Mahley RW, Weisgraber KH. Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100. Lancet 1992;339:598.
4. [4] Semenkovich CF, Ostlund RE. Estrogens induce low-density lipoprotein receptor activity and decrease intracellular cholesterol in human hepatoma cell line HepG2. Biochemistry 1987;26:4987.
5. [5] McKeone BJ, Patsch JR, Pownall HJ. Plasma triglycerides determine low density lipoprotein composition, physical properties and cell-specific binding in cultured cells. J Clin Invest 1993;91:1926.
6. [6] Hoeg JM, Demosky SJ, Lackner KJ, Osborne JC, Oliver C, Brewer HB. The expressed hepatic receptor for low-density lipoprotein differs from the fibroblast low-density lipoprotein receptor. Biochim Biophys Acta 1986;876:13.
7. [7] Mamotte CDS, van Bockxmeer FM. A robust method for screening and confirmation of familial defective apolipoprotein B-100. Clin Chem 1993;39:118.
8. [8] Edelstein C, Scanu AM. Precautionary measures for collecting blood destined for lipoprotein isolation. In: Segrest JP and Albers JJ. (eds). Methods in Enzymology: Plasma lipoproteins. Orlando: Academic Press. 1986;128:151.
9. [9] Redgrave TG, Roberts DC, West CE. Separation of plasma lipoproteins by density-gradient ultracentritugation. Anal Biochem 1975;65:42.
10. [10] Bilheimer DW, Eisenberg S, Levy RT. The metabolism of very low density lipoprotein proteins: I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta 1972;260:212.
11. [11] Goldstein JL, Basu SK, Brown MS. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. In: Fleischer S and Fleischer B. (eds). Methods in Enzymology: Membrane Biogenesis - Processing and Recycling. New York: Academic Press, 1983;98:241.
12. [12] Chappell DA, Fry GL, Wakniz MA, Berns JJ. Evidence for the isomerization during binding of apolipoprotein-B-100 to low density lipoprotein receptors. J Biol Chem 1992;267:270.
13. [13] Friedl W, Ludwig EH, Balestra ME et al. Apolipoprotein B gene mutations in Austrian subjects with heart disease and their kindred. Arteriosclerosis Thromb 1991;11:371.
14. [14] Myant NB, Gallagher JJ, Knight BL et al. Clinical signs of familial hypercholesterolaemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function. Arteriosclerosis Thromb 1991;11:691.
15. [15] Innerarity TL, Weisgraber KH, Arnold KS et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 1987;84:6919.
16. [16] Corsini A, Mazzotti M, Fumagalli R, Catapano AL, Romano L, Romano C. Poor response to simvastatin in familial defective apo-B-100. Lancet 1991;337:305 (Lett.).
17. [17] Vega GL, Grundy SM. Studies on mechanisms for enhanced clearance of low-density lipoproteins in patients with primary hypertriglyceridaemia. J Intern Med 1989;226:5.
18. [18] Havekes LM, Verboom H, De Wit E, Yap SH, Princen HMG. Regulation of low density lipoprotein receptor activity in primary cultures of human hepatocytes by serum lipoproteins. Hepatology 1986;6:1356.
19. [19] Arnold KS, Balestra ME, Krauss RM, Curtiss LK, Young SG, Innerarity TL. Isolation of allele-specific, receptor-binding-defective low density lipoproteins from familial defective apolipoprotein B-100 subjects. J Lip Res 1994;35:1469.
20. [20] Illingworth DR. HMG CoA reductase inhibitors. Curr Opin Lipidol 1991;2:24.
21. [21] Arad Y, Ramakrishnan R, Ginsberg N. Lovastatin therapy reduces low density lipoprotein apo B levels in subjects with combined hyperlipidaemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apo B production. J Lip Res 1990;31:567.
22. [22] Malmendier CL, Lontie JF, Delcroix C, Magot T. Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normo-cholesterolaemic human volunteers. Atherosclerosis 1989;80:101.
23. [23] Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolaemia heterozygotes. Proc Natl Acad Sci USA 1983;80:4124.
24. [24] Marz W, Baumstark MW, Scharnagl H et al. Accumulation of 'small dense' low density lipoproteins (LDL) in a homozygous patient with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor. J Clin Invest 1993;92:2922.
25. [25] Maher VMG, Gallagher JJ, Myant NB. The binding of very low density lipoprotein remnants to the low density lipoprotein receptor in familial defective apolipoprotein B-100. Atherosclerosis 1993;102:51.